Clinical trial
Pegasys® in Patients With Myeloproliferative Diseases
NCT00452023 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00452023 |
|---|---|
| Title | Pegasys® in Patients With Myeloproliferative Diseases |
| Official title | PEG IFN-alpha2a (Pegasys®) Therapy in Patients With Chronic Myeloproliferative Diseases (Excluding Philadelphia Chromosome Positive Chronic Myeloid Leukemia) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myeloproliferative Disorders |
| Intervention type | Drug |
| Interventions | IFN-alpha2a |
| Enrollment | 83 |
| Start date | Apr 7, 2005 |
| Primary completion | May 26, 2023 |
| Completion | May 26, 2023 |
| First posted | Mar 26, 2007 |
| Last update posted | Dec 11, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: